Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEA K KREKOW

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1982641361
CMS profile
361975
Location
BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$11.96

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $11.96 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $11.96 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEA K KREKOW

NPI 1982641361 · CMS profile ID 361975

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982641361?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEA K KREKOW, NPI 1982641361, CMS profile ID 361975. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982641361?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LEA K KREKOW, NPI 1982641361, CMS profile ID 361975. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982641361?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LEA K KREKOW, NPI 1982641361, CMS profile ID 361975, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982641361?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.9603/12/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672947207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.96 1
PY2021 $11.92 1
PY2022 $37.12 2
PY2023 $161.06 8
PY2024 $149.91 8
PY2025 $253.50 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $27,923.22 2
PY2024 Principal investigator $20,648.10 6
PY2023 Principal investigator $44,196.84 17
PY2022 Principal investigator $35,021.60 18
PY2021 Principal investigator $144,101.20 50
PY2020 Principal investigator $72,627.04 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $3,107.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
B-59GBG96-GEPARDOUZEMO39875 No dispute reported 06/30/2026 836026717
Principal investigator 1 Seagen Inc. $1,445.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668769
Principal investigator 1 Seagen Inc. $1,841.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668993
Principal investigator 1 Seagen Inc. $1,445.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669015
Principal investigator 1 Seagen Inc. $1,445.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669017
Principal investigator 1 Seagen Inc. $1,445.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669019
Principal investigator 1 Seagen Inc. $2,150.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668755
Principal investigator 1 Seagen Inc. $450.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668761
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668763
Principal investigator 1 Seagen Inc. $4,123.96 09/27/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669031
Principal investigator 1 Seagen Inc. $4,123.96 09/27/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669037
Principal investigator 1 Seagen Inc. $1,445.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669005
Principal investigator 1 Seagen Inc. $2,150.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669007
Principal investigator 1 Seagen Inc. $500.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669009
Principal investigator 1 Seagen Inc. $1,445.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669021
Principal investigator 1 Seagen Inc. $1,445.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669023
Principal investigator 1 Seagen Inc. $1,445.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669025
Principal investigator 1 Seagen Inc. $4,123.96 08/26/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669029
Principal investigator 1 Seagen Inc. $4,123.96 08/26/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669035
Principal investigator 1 Seagen Inc. $3,430.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669003
Principal investigator 1 Seagen Inc. $4,123.96 07/27/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669027
Principal investigator 1 Seagen Inc. $4,123.96 07/27/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792669033
Principal investigator 1 Seagen Inc. $2,150.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668995
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668997
Principal investigator 1 Seagen Inc. $4,123.96 06/28/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668737
Principal investigator 1 Seagen Inc. $4,123.96 06/28/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668751
Principal investigator 1 Genentech, Inc. $6,796.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
NSABP PROTOCOL B 59 GBG 96 GEPARDOUZE No dispute reported 06/30/2026 836026425
Principal investigator 1 Seagen Inc. $2,000.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668701
Principal investigator 1 Seagen Inc. $4,263.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668703
Principal investigator 1 Seagen Inc. $2,150.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668691
Principal investigator 1 Seagen Inc. $4,123.96 05/03/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668735
Principal investigator 1 Seagen Inc. $4,123.96 05/03/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668749
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668677
Principal investigator 1 Seagen Inc. $2,150.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668679
Principal investigator 1 Seagen Inc. $3,230.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668689
Principal investigator 1 Seagen Inc. $4,123.96 04/05/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668733
Principal investigator 1 Seagen Inc. $4,123.96 04/05/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668747
Principal investigator 1 Seagen Inc. $1,950.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668665
Principal investigator 1 Seagen Inc. $4,123.96 03/11/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668729
Principal investigator 1 Seagen Inc. $4,123.96 03/11/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668743
Principal investigator 1 Seagen Inc. $4,123.96 02/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668727
Principal investigator 1 Seagen Inc. $4,123.96 02/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668741
Principal investigator 1 Seagen Inc. $2,145.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668673
Principal investigator 1 Seagen Inc. $2,140.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668675
Principal investigator 1 Seagen Inc. $4,123.96 02/02/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668725
Principal investigator 1 Seagen Inc. $4,123.96 02/02/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668739
Principal investigator 1 Seagen Inc. $3,636.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668667
Principal investigator 1 Seagen Inc. $956.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668669
Principal investigator 1 Seagen Inc. $4,123.96 01/12/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668731
Principal investigator 1 Seagen Inc. $4,123.96 01/12/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792668745